Compounded vs FDA HRT: Evidence, Safety, and Cost Comparison

The compounded vs FDA HRT debate has shaped how perimenopausal and menopausal women access hormone therapy in the United States for more than two decades. Both categories can deliver bioidentical estradiol, progesterone, or testosterone — but they differ sharply in regulatory oversight, clinical trial evidence, dosing reliability, and out-of-pocket cost. Major guidelines from the North American Menopause Society (NAMS), the American College of Obstetricians and Gynecologists (ACOG), and the Endocrine Society generally favor FDA-approved options as first-line, while reserving compounding for specific clinical situations. This guide walks through the regulatory framework, the evidence base, costs, and how telehealth clinics typically navigate the choice.

Key facts at a glance

• FDA-approved HRT products complete premarket clinical trials for safety, efficacy, and manufacturing consistency; compounded HRT does not.¹
• A 2020 National Academies (NASEM) consensus report found no high-quality evidence supporting routine compounded bioidentical hormone therapy (cBHT) over FDA-approved alternatives.²
• Typical out-of-pocket cost difference: roughly $20-$60/month (FDA-approved generic estradiol) versus $75-$300/month (compounded pellets, troches, custom creams).
• NAMS, ACOG, and the Endocrine Society recommend reserving compounding for documented intolerance to FDA-approved excipients or for doses not commercially available.³ ⁴

What "compounded vs FDA HRT" actually means

FDA-approved hormone therapy refers to commercially manufactured drug products — patches such as Climara and Vivelle-Dot, oral micronized progesterone (Prometrium), estradiol gels (Divigel, EstroGel), vaginal estradiol (Estrace, Vagifem), and combination tablets (Activella) — that have completed the FDA's New Drug Application process. Each product carries an FDA label with dosing, contraindications, and adverse event data. The FDA's consumer guidance on menopause and hormones lists more than 30 such approved products.⁵

Compounded HRT is a customized formulation prepared by a licensed pharmacy on a per-prescription basis. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, traditional compounding pharmacies prepare individualized prescriptions overseen by state pharmacy boards. Section 503B "outsourcing facilities" prepare larger batches under federal current Good Manufacturing Practice (cGMP) rules. Neither pathway requires the premarket clinical trials FDA-approved drugs must complete.⁵ Compounded products commonly include estradiol/estriol blends (Bi-Est), estradiol/estriol/estrone (Tri-Est), subcutaneous testosterone or estradiol pellets, sublingual troches, and custom-strength topical creams.¹

The 2020 NASEM report explicitly noted that "bioidentical" is not a regulatory term: both FDA-approved estradiol and compounded estradiol are chemically identical to endogenous estradiol.² The distinction is regulatory and evidentiary, not chemical.

How the evidence compares

The evidence base for FDA-approved HRT spans hundreds of randomized controlled trials, including the Women's Health Initiative (WHI), the Early versus Late Intervention Trial with Estradiol (ELITE), and the Kronos Early Estrogen Prevention Study (KEEPS). Long-term cohort follow-up has clarified that for women under age 60 or within 10 years of menopause onset, the benefit-risk profile of FDA-approved transdermal estradiol with micronized progesterone is generally favorable for vasomotor symptoms, sleep, and bone density.³

The 2020 NASEM consensus reviewed published evidence on compounded bioidentical hormone therapy and concluded the data were insufficient to support routine clinical use. Specific concerns included:²

1. Dosing accuracy. Independent assays of compounded formulations have shown potency variation of 30% or more from labeled strength, with some studies finding super- or sub-potent samples.²
2. Sterility and stability. Topical creams and injectables are vulnerable to microbial contamination and shelf-life uncertainty without batch testing.
3. Salivary monitoring. Compounding pharmacies often pair products with salivary hormone tests that NAMS, ACOG, and the Endocrine Society consider clinically uninterpretable for dosing decisions.³ ⁴
4. Endometrial safety. Compounded "natural progesterone" creams typically deliver insufficient systemic progesterone to protect the endometrium in women using systemic estrogen, raising the theoretical risk of unopposed-estrogen exposure.⁶

A 2019 analysis of Women's Health Initiative follow-up data underscored that endometrial cancer risk rises sharply when systemic estrogen is not adequately balanced by progestogen.⁷ FDA-approved combination products and oral micronized progesterone (Prometrium) have established progestogenic potency; many compounded progesterone creams do not.

By contrast, the Endocrine Society Clinical Practice Guideline and the 2022 NAMS Position Statement explicitly support FDA-approved bioidentical estradiol and micronized progesterone as evidence-backed options that share the molecular profile women often seek when they ask about "bioidenticals."³ ⁸

Comparing common formulations

This is a comparison of regulated formulation categories — not a clinical recommendation. Decisions about hormone therapy should be made with a qualified clinician.

| Category | Examples | Regulatory status | Evidence base | |---|---|---|---| | Transdermal estradiol patch | Climara, Vivelle-Dot, Minivelle | FDA-approved | Multiple RCTs; preferred when avoiding first-pass liver metabolism³ | | Oral micronized progesterone | Prometrium (generic available) | FDA-approved | RCT data on endometrial protection and sleep⁸ | | Estradiol gel/spray | Divigel, EstroGel, Evamist | FDA-approved | Pharmacokinetic equivalence to patch³ | | Vaginal estradiol | Estrace cream, Vagifem, Imvexxy | FDA-approved | Effective for genitourinary syndrome of menopause³ | | Compounded Bi-Est / Tri-Est creams | Custom estriol/estradiol/estrone blends | 503A compounded | No FDA review; estriol not FDA-approved as a stand-alone drug¹ ⁵ | | Subcutaneous hormone pellets | Estradiol or testosterone pellets | 503A compounded | Not FDA-approved; NAMS notes supraphysiologic serum levels³ | | Sublingual troches / custom creams | Patient-specific strengths | 503A compounded | Limited published pharmacokinetic data¹ |

Editorial note: ACOG Committee Opinion 532 (reaffirmed 2020) supports compounding only when "a commercially available product is not appropriate" — for example, documented allergy to an FDA-approved product's excipient or a dose not available commercially.⁴ Women considering compounding are typically encouraged to discuss this rationale explicitly with a clinician before proceeding.

Telehealth provider options

Most major menopause telehealth clinics prescribe FDA-approved bioidentical estradiol and micronized progesterone as their primary formulary. Approaches differ:

• Midi Health — NAMS-certified clinicians, accepts most insurance, prescribes primarily FDA-approved transdermal estradiol and oral micronized progesterone.
• Alloy Women's Health — cash-pay subscription, async-first model, FDA-approved formulary with a vetted pharmacy partner.
• Winona — cash-pay telehealth that works with compounding pharmacies for some formulations; intake clarifies which products are commercially available versus compounded.
• Gennev — board-certified gynecologists, in-network with several commercial plans, generally prescribes FDA-approved bioidentical options.

Before signing up, women often check whether the provider's formulary aligns with their preferences on FDA-approved versus compounded products, and how progesterone is delivered for endometrial protection.

Safety, contraindications, and when to see a clinician

The contraindications for hormone therapy are similar across formulations: known or suspected breast cancer, estrogen-sensitive cancers, active or prior venous thromboembolism, active liver disease, unexplained vaginal bleeding, and known hypersensitivity.³ Both FDA-approved and compounded products share these absolute contraindications.

Additional considerations specific to compounded products include:

• Endometrial protection. Women with an intact uterus using systemic estrogen need adequate progestogen. Compounded progesterone creams have historically been associated with insufficient endometrial protection.⁶ ⁷
• Dosing verification. Because compounded products are not assayed batch-to-batch, dose verification typically depends on clinical response rather than reliable serum monitoring.²
• Pellet-specific concerns. Subcutaneous pellets cannot be removed quickly if adverse events develop, and serum estradiol can reach supraphysiologic ranges.³

Anyone considering hormone therapy — compounded or FDA-approved — is generally advised to discuss personal and family history (especially breast cancer, clotting disorders, cardiovascular disease, migraine with aura) with a clinician before starting. Persistent abnormal vaginal bleeding, new chest pain, leg swelling, severe headache, or visual changes during HRT warrant prompt medical evaluation.

Cost & insurance considerations

Costs vary widely by formulation, pharmacy, and insurance plan. The figures below are typical 2026 U.S. retail ranges and should not be read as guaranteed pricing.

• Generic FDA-approved estradiol patch (twice-weekly): roughly $20-$45/month with commercial insurance; $40-$80/month cash.
• Generic oral micronized progesterone 100 mg: roughly $15-$35/month with insurance; $40-$70/month cash.
• FDA-approved vaginal estradiol (cream or tablet): roughly $30-$70/month with insurance; $150-$300/month cash without coupons.
• Compounded Bi-Est cream: roughly $50-$120/month, typically cash-pay.
• Compounded progesterone cream/troche: roughly $40-$90/month, typically cash-pay.
• Subcutaneous hormone pellets: roughly $300-$650 per insertion, with insertions every 3-5 months; rarely covered by insurance.

Most commercial plans cover FDA-approved bioidentical estradiol and oral micronized progesterone with standard prior authorization in line with the 2022 NAMS Position Statement.³ Compounded products are usually paid out-of-pocket and may not qualify for HSA or FSA reimbursement without a letter of medical necessity. A separate review of pricing dynamics is available in the how much does HRT cost without insurance guide.

Frequently asked questions

Is compounded HRT safer than FDA-approved HRT? Current evidence does not support that claim. FDA-approved hormone therapy products have demonstrated batch-to-batch potency, sterility, and absorption profiles. The 2020 NASEM report and 2022 NAMS Position Statement note compounded bioidentical hormone therapy lacks comparable safety data.

Why do some clinicians still prescribe compounded HRT? Compounded HRT can address documented allergies to inactive ingredients, dose strengths not available commercially, or unique delivery routes. ACOG Committee Opinion 532 supports compounding for these specific clinical reasons, not as a routine substitute for FDA-approved products.

Are hormone pellets considered compounded or FDA-approved? Subcutaneous hormone pellets are compounded products. No estradiol or testosterone pellet has been FDA-approved for menopause symptom relief in the United States. NAMS has raised concerns about supraphysiologic serum levels seen with pellets.

Does insurance cover compounded HRT? Most commercial insurance plans cover FDA-approved estradiol patches, gels, and oral micronized progesterone. Compounded pellets, troches, and custom creams are usually paid out-of-pocket and may not qualify for HSA or FSA reimbursement without a letter of medical necessity.

Can telehealth clinics prescribe both compounded and FDA-approved HRT? Most major menopause telehealth platforms prescribe FDA-approved bioidentical options first. A few work with 503A compounding pharmacies when clinically indicated. Approaches vary; provider intake forms typically clarify the formulary.

How is compounded HRT regulated if not by the FDA? Section 503A pharmacies are regulated by state boards of pharmacy with FDA oversight for adverse events. Section 503B outsourcing facilities follow federal cGMP rules. Neither category requires the premarket clinical trials FDA-approved drugs must complete.

Sources

1. Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. Mayo Clin Proc. 2011;86(7):673-680. https://pubmed.ncbi.nlm.nih.gov/21531972/
2. National Academies of Sciences, Engineering, and Medicine. The Clinical Utility of Compounded Bioidentical Hormone Therapy. 2020. https://nap.nationalacademies.org/catalog/25791/the-clinical-utility-of-compounded-bioidentical-hormone-therapy-a-review
3. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
4. ACOG Committee Opinion No. 532: Compounded bioidentical menopausal hormone therapy. Obstet Gynecol. 2012;120(2 Pt 1):411-415 (reaffirmed 2020). https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2012/08/compounded-bioidentical-menopausal-hormone-therapy
5. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
6. Pinkerton JV, Santoro N. Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women. Menopause. 2015;22(9):926-936. https://pubmed.ncbi.nlm.nih.gov/25803671/
7. Constantine GD, Kessler G, Graham S, Goldstein SR. Increased incidence of endometrial cancer following the Women's Health Initiative: an assessment of risk factors. J Womens Health (Larchmt). 2019;28(2):237-243. https://pubmed.ncbi.nlm.nih.gov/30481102/
8. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. https://pubmed.ncbi.nlm.nih.gov/26444994/

Related brands & guides

Updated May 30, 2026. Medically reviewed by Jane Smith, MD.

Related reading: Bioidentical hormones explained · How much does HRT cost without insurance · HRT vs non-hormonal options for menopause

Compare telehealth menopause clinics: Midi Health · Alloy Women's Health · Winona · Gennev